Safety and Efficacy of Nerandomilast in Patients With Pulmonary Fibrosis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials - PubMed
12 hours ago
- #Pulmonary Fibrosis
- #PDE4 Inhibitors
- #Meta-Analysis
- Nerandomilast, a PDE4 inhibitor, shows potential in slowing pulmonary fibrosis progression.
- Meta-analysis of 4 RCTs (n=2515) found nerandomilast significantly reduced FVC decline vs. placebo (MD: 69.25 mL).
- No significant improvement in DLCO was observed with nerandomilast.
- Lower pooled risk of all-cause mortality (RR: 0.68) without increased adverse events.
- Heterogeneity in fibrosis phenotypes and trial designs calls for further large-scale RCTs.